Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion79d agoSheikh Zayed Medical College Rahim Yar Khan — ursodeoxycholic acid (Phase II Trial Completion)ursodeoxycholic acid

Therapy area: Gastrointestinal, Metabolic Disorders. Indication: Hyperbilirubinemia, Jaundice

full page →ursodeoxycholic acid →source: globaldata

Apr 30, 2026phase 2 completion79d agoCelerion Inc — ORX-750 (Phase II Trial Completion)ORX-750

Therapy area: Central Nervous System. Indication: Idiopathic Hypersomnia (IH), Narcolepsy, Type 1 Narcolepsy (Narcolepsy with Cataplexy), Type 2 Narcolepsy (Narcolepsy without Cataplexy)

full page →ORX-750 →source: globaldata

Apr 30, 2026phase 2 completion79d agoDow University of Health Sciences — simvastatin (Phase II Trial Completion)simvastatin

Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

full page →simvastatin →source: globaldata

Apr 30, 2026phase 2 completion79d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

full page →apixaban ODT →source: globaldata

Apr 30, 2026phase 2 completion79d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 2 completion79d agoXijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)pertuzumab + trastuzumab

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)

full page →pertuzumab + trastuzumab →source: globaldata

Apr 30, 2026phase 2 completion79d agoLTR Pharma Ltd — vardenafil (Phase II Trial Completion)vardenafil

Therapy area: Central Nervous System. Indication: Erectile Dysfunction

full page →vardenafil →source: globaldata

Apr 30, 2026phase 2 completion79d agoCentrum Clinic IVF Center — follitropin (Phase II Trial Completion)follitropin

Therapy area: Women's Health. Indication: Female Infertility

full page →follitropin →source: globaldata

Apr 30, 2026phase 2 completion79d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

Therapy area: Cardiovascular. Indication: Hypotension

full page →ephedrine →source: globaldata

Apr 30, 2026phase 2 completion79d agoAthletic Greens International Inc — undisclosed mineral supplement (Phase II Trial Completion)undisclosed mineral supplement

Therapy area: Central Nervous System. Indication: Sleep Disorders

full page →undisclosed mineral supplement →source: globaldata

Apr 30, 2026phase 2 completion79d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion79d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

full page →tozorakimab →source: globaldata

Apr 30, 2026phase 2 completion79d agoCurtin University — influenza vaccine (Phase II Trial Completion)influenza vaccine

Therapy area: Cardiovascular. Indication: Myocardial Infarction

full page →influenza vaccine →source: globaldata

Apr 30, 2026phase 2 completion79d agoBeijing Sanbo Brain Hospital — ceritinib (Phase II Trial Completion)ceritinib

Therapy area: Oncology. Indication: Mesenchymal Tumor

full page →ceritinib →source: globaldata

Apr 30, 2026phase 2 completion79d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata

Apr 30, 2026phase 2 completion79d agoWuhan Union Hospital — cadonilimab (Phase II Trial Completion)cadonilimab

Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

full page →cadonilimab →source: globaldata

Apr 30, 2026phase 2 completion79d agoBeijing Jishuitan Hospital — undisclosed anesthetic drug (Phase II Trial Completion)undisclosed anesthetic drug

Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Pain

full page →undisclosed anesthetic drug →source: globaldata

Apr 30, 2026phase 2 completion79d agoHospital General Universitario Morales Meseguer — cefditoren pivoxil (Phase II Trial Completion)cefditoren pivoxil

Therapy area: Gastrointestinal. Indication: Colonic Diverticulitis

full page →cefditoren pivoxil →source: globaldata

Apr 30, 2026phase 2 completion79d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

Therapy area: Oncology. Indication: Lung Cancer

full page →canakinumab →source: globaldata

Apr 30, 2026phase 2 completion79d agoDirect Biologics LLC — DB-3Q (Phase II Trial Completion)DB-3Q

Therapy area: Gastrointestinal. Indication: Anal Fistula, Crohn's Disease (Regional Enteritis)

full page →DB-3Q →source: globaldata

Apr 30, 2026phase 2 completion79d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Endometrial Cancer

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion79d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion79d agoInnovent Biologics Inc — mazdutide (Phase II Trial Completion)mazdutide

Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)

full page →mazdutide →source: globaldata

Apr 30, 2026phase 2 completion79d agoBeijing Chao-Yang Hospital — bupivacaine liposome (Phase II Trial Completion)bupivacaine liposome

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →bupivacaine liposome →source: globaldata

Apr 30, 2026phase 2 completion79d agoChacha Nehru Bal Chikitsalaya — Isobaric bupivacaine (Phase II Trial Completion)Isobaric bupivacaine

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →Isobaric bupivacaine →source: globaldata

Apr 30, 2026phase 2 completion79d agoCarlo Bo University of Urbino — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

Therapy area: Gastrointestinal. Indication: Diarrhea

full page →(amoxicillin + clavulanic acid) →source: globaldata

Apr 30, 2026phase 2 completion79d agoHuzhou Maternity and Child Care Hospital — esketamine (Phase II Trial Completion)esketamine

Therapy area: Central Nervous System. Indication: Post-Operative Pain, Sleep Disorders

full page →esketamine →source: globaldata

Apr 30, 2026phase 2 completion79d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →JTM-102 →source: globaldata

Apr 30, 2026phase 2 completion79d agoUniversity of Udine — cholecalciferol (Phase II Trial Completion)cholecalciferol

Therapy area: Musculoskeletal Disorders. Indication: Sarcopenia

full page →cholecalciferol →source: globaldata

Apr 30, 2026phase 2 completion79d agoShionogi & Co Ltd — daridorexant hydrochloride (Phase II Trial Completion)daridorexant hydrochloride

Therapy area: Central Nervous System. Indication: Insomnia

full page →daridorexant hydrochloride →source: globaldata

Apr 30, 2026phase 2 completion79d agoFirst Affiliated Hospital of Kunming Medical University — sugammadex (Phase II Trial Completion)sugammadex

Therapy area: Non Malignant Disorders, Women's Health. Indication: Unspecified Gynecological Disorders, Uterine Leiomyoma (Uterine Fibroids)

full page →sugammadex →source: globaldata

Apr 30, 2026phase 2 completion79d agoInstitute of Liver and Biliary Sciences — darbepoetin alfa (Phase II Trial Completion)darbepoetin alfa

Therapy area: Gastrointestinal. Indication: Decompensated Cirrhosis, Liver Cirrhosis

full page →darbepoetin alfa →source: globaldata

Apr 30, 2026phase 2 completion79d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion79d agoAristotle University of Thessaloniki — oleocanthal (Phase II Trial Completion)oleocanthal

Therapy area: Central Nervous System. Indication: Mild Cognitive Impairment

full page →oleocanthal →source: globaldata

Apr 30, 2026phase 2 completion79d agoBiogen Inc — DNL-151 (Phase II Trial Completion)DNL-151

Therapy area: Central Nervous System. Indication: Parkinson's Disease

full page →DNL-151 →source: globaldata

Apr 30, 2026phase 2 completion79d agoAffiliated Stomatological Hospital of Guangxi Medical University — autologous platelet rich plasma (Phase II Trial Completion)autologous platelet rich plasma

Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Arthralgia (Joint Pain), Osteoarthritis

full page →autologous platelet rich plasma →source: globaldata

Apr 30, 2026phase 2 completion79d agoVertex Pharmaceuticals Inc — VX-993 (Phase II Trial Completion)VX-993

Therapy area: Central Nervous System. Indication: Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain

full page →VX-993 →source: globaldata

Apr 30, 2026phase 2 completion79d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata

Apr 30, 2026phase 2 completion79d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion79d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion79d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion79d agoFundacion para la Investigacion Biomedica Hospital Clinico San Carlos — cromolyn sodium (Phase II Trial Completion)Gastrocrom

Therapy area: Central Nervous System. Indication: Multiple Sclerosis

full page →Gastrocrom →source: globaldata

Apr 30, 2026phase 2 completion79d agoGachon University Gil Medical Center — Wegovy (Phase II Trial Completion)Wegovy Pill

Therapy area: Metabolic Disorders. Indication: Obesity

full page →Wegovy Pill →source: globaldata

Apr 30, 2026phase 2 completion79d agoWannan Medical College First Affiliated Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

Therapy area: Undisclosed. Indication: Unspecified

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 2 completion79d agoWestern New England University — grape powder (Phase II Trial Completion)grape powder

Therapy area: Central Nervous System. Indication: Cognitive Disorders

full page →grape powder →source: globaldata

Apr 30, 2026phase 2 completion79d agoKLE College of Pharmacy, Belagavi — undisclosed immunosuppressive drug (Phase II Trial Completion)undisclosed immunosuppressive drug

Therapy area: Genito Urinary System. Indication: Nephrotic Syndrome

full page →undisclosed immunosuppressive drug →source: globaldata

Apr 30, 2026phase 2 completion79d agoUniversity of Minnesota — Lactobacillus casei (Phase II Trial Completion)Lactobacillus casei

Therapy area: Musculoskeletal Disorders. Indication: Muscle Injury, Unspecified Musculoskeletal Disorders

full page →Lactobacillus casei →source: globaldata

Apr 30, 2026phase 2 completion79d agoArrae Inc — Aframomum melegueta extract (Phase II Trial Completion)Aframomum melegueta extract

Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

full page →Aframomum melegueta extract →source: globaldata

Apr 30, 2026phase 2 completion79d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion79d agoCharak Ayurvedic Pharmacy, Paprola — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Hyperuricemia, Unspecified Musculoskeletal Disorders

full page →ayurvedic medicine →source: globaldata

← prev

page 15 of 147

Week of Apr 27, 2026